The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Smith Hunter C since 2018.
This trader's CIK number is 1636385.
At the time of last reporting, Smith Hunter C was the Chief Financial Officer of Rhythm Pharmaceuticals, Inc.. (stock ticker symbol RYTM).
Also see all insider trading activities at Rhythm Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | RYTM | 0 | $0 | 97,870 | $7,695,090 | 113,599 | $692,084 |
| 2024 | RYTM | 0 | $0 | 19,049 | $778,754 | 21,832 | $72,240 |
| 2023 | RYTM | 0 | $0 | 52,100 | $1,852,792 | 58,407 | $357,759 |
| 2022 | RYTM | 0 | $0 | 8,380 | $35,872 | 27,344 | $0 |
| 2021 | RYTM | 0 | $0 | 0 | $0 | 9,000 | $61,920 |
| 2020 | RYTM | 0 | $0 | 0 | $0 | 13,650 | $93,912 |
| 2019 | RYTM | 0 | $0 | 0 | $0 | 13,000 | $89,440 |
| 2018 | RYTM | 0 | $0 | 0 | $0 | 3,000 | $20,640 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-12 | RYTM | Option Ex | 24,611 | 6.88 | 169,323 |
| 2025-08-13 | RYTM | Option Ex | 3,477 | 6.88 | 23,921 |
| 2025-08-12 | RYTM | Sale | 24,611 | 96.33 | 2,370,826 |
| 2025-08-13 | RYTM | Sale | 3,477 | 96.00 | 333,792 |
| 2025-07-09 | RYTM | Sale | 42,120 | 78.69 | 3,314,212 |
| 2025-07-09 | RYTM | Option Ex | 42,120 | 6.88 | 289,785 |
| 2025-07-07 | RYTM | Option Ex | 6,986 | 6.88 | 48,063 |
| 2025-05-30 | RYTM | Sale | 23,400 | 61.23 | 1,432,688 |
| 2025-05-30 | RYTM | Option Ex | 23,400 | 6.88 | 160,992 |
| 2025-02-16 | RYTM | Option Ex | 6,600 | .00 | 0 |
| 2025-02-19 | RYTM | Sale | 2,215 | 57.22 | 126,742 |
| 2025-02-12 | RYTM | Sale | 751 | 56.30 | 42,285 |
| 2025-02-11 | RYTM | Sale | 1,296 | 57.52 | 74,545 |
| 2025-02-11 | RYTM | Option Ex | 2,343 | .00 | 0 |
| 2025-02-09 | RYTM | Option Ex | 4,062 | .00 | 0 |
| 2024-03-19 | RYTM | Sale | 15,515 | 39.22 | 608,498 |
| 2024-02-11 | RYTM | Option Ex | 2,344 | .00 | 0 |
| 2024-02-13 | RYTM | Sale | 709 | 49.82 | 35,322 |
| 2024-02-09 | RYTM | Option Ex | 4,063 | .00 | 0 |
| 2024-02-12 | RYTM | Sale | 1,209 | 51.38 | 62,118 |
| 2024-02-01 | RYTM | Sale | 1,616 | 45.06 | 72,816 |
| 2024-02-01 | RYTM | Option Ex | 4,925 | .00 | 0 |
| 2023-12-29 | RYTM | Option Ex | 10,500 | 6.88 | 72,240 |
| 2023-12-05 | RYTM | Option Ex | 7,026 | 6.88 | 48,338 |
| 2023-12-06 | RYTM | Option Ex | 20,000 | 6.88 | 137,600 |
| 2023-12-05 | RYTM | Sale | 7,026 | 35.06 | 246,359 |
| 2023-12-06 | RYTM | Sale | 20,000 | 40.00 | 800,000 |
| 2023-11-24 | RYTM | Option Ex | 10,974 | 6.88 | 75,501 |
| 2023-11-24 | RYTM | Sale | 10,974 | 35.02 | 384,331 |
| 2023-11-14 | RYTM | Option Ex | 12,000 | 6.88 | 82,560 |
| 2023-11-14 | RYTM | Sale | 12,000 | 30.38 | 364,572 |
| 2023-06-16 | RYTM | Option Ex | 2,000 | 6.88 | 13,760 |
| 2023-02-11 | RYTM | Option Ex | 2,344 | .00 | 0 |
| 2023-02-14 | RYTM | Sale | 702 | 26.87 | 18,862 |
| 2023-02-09 | RYTM | Sale | 1,398 | 27.66 | 38,668 |
| 2023-02-09 | RYTM | Option Ex | 4,063 | .00 | 0 |
| 2022-07-01 | RYTM | Sale | 7,547 | 4.08 | 30,791 |
| 2022-06-30 | RYTM | Option Ex | 25,000 | .00 | 0 |
| 2022-02-11 | RYTM | Option Ex | 2,344 | .00 | 0 |
| 2022-02-15 | RYTM | Sale | 833 | 6.10 | 5,081 |
| 2021-04-21 | RYTM | Option Ex | 5,000 | 6.88 | 34,400 |
| 2021-01-19 | RYTM | Option Ex | 4,000 | 6.88 | 27,520 |
| 2020-03-30 | RYTM | Option Ex | 3,900 | 6.88 | 26,832 |
| 2020-03-13 | RYTM | Option Ex | 3,500 | 6.88 | 24,080 |
| 2020-01-28 | RYTM | Option Ex | 6,250 | 6.88 | 43,000 |
| 2019-07-11 | RYTM | Option Ex | 10,000 | 6.88 | 68,800 |
| 2019-01-31 | RYTM | Option Ex | 3,000 | 6.88 | 20,640 |
| 2018-09-05 | RYTM | Option Ex | 3,000 | 6.88 | 20,640 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Smith Hunter C (Chief Financial Officer of Rhythm Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.